Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
J

BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive and R/R CLL After 3-Year FollowUp Yielded High Responsive Durable Rates

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jennifer Woyach
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jennifer Woyach
444 views
October 18, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…

Feat. M. Shadman
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
15:21
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
06:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…

Feat. A. Kittai
08:45
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…

Feat. V. Yazbeck
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
11:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…

Feat. G. Gaidano
18:01
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…

Feat. J. Rhodes
05:12
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …

Feat. N. Shah
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

13:16
ASH 2022 Conference Coverage

Experts Discuss Key Updates in CLL

Feat. S. O'Brien, C. Coombs
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
28:43
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Scripps MD Anderson Cancer Center Updates on CLL/SLL Frontline Thera…

Feat. S. O'Brien